Validation of population pharmacokinetic parameters of phenytoin using the parallel Michaelis-Menten and first-order elimination model

Therapeutic Drug Monitoring

Volumn 22, Issue 3, 2000, Pages 313-319

  Valodia, Praneet N ^a   Seymour, Michael A ^b   McFadyen, Margaret L ^c   Miller, Raymond ^c   Folb, Peter I ^d  

^a UNIVERSITY OF THE WESTERN CAPE   (South Africa)

^b Warner Lambert Pty Ltd   (South Africa)

^c UNIVERSITY OF KWAZULU NATAL   (South Africa)

^d UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

Linear clearance; Phenytoin; Population pharmacokinetic parameters; Validation

Indexed keywords

PHENYTOIN;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG ELIMINATION; EPILEPSY; FEMALE; FIRST PASS EFFECT; HUMAN; MAJOR CLINICAL STUDY; MALE; MICHAELIS MENTEN KINETICS; PRIORITY JOURNAL; VALIDATION PROCESS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTICONVULSANTS; DATA INTERPRETATION, STATISTICAL; DOSE-RESPONSE RELATIONSHIP, DRUG; EPILEPSY; FEMALE; HUMANS; LINEAR MODELS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; NONLINEAR DYNAMICS; PHENYTOIN; PREDICTIVE VALUE OF TESTS; REPRODUCIBILITY OF RESULTS;

EID: 0034041112     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-200006000-00013     Document Type: Article

References (19)

1. Bochner F, Hooper WD, Tyrer JH, Eadie MJ. Effect of dosage increments on blood phenytoin concentrations. J Neurol Neurosurg Psych 1972;35:873-76.
2. Ludden TM. Nonlinear Pharmacokinetics. Clinical implications. Clin Pharmacokinet 1991;20:429-46.
3. Ludden TM, Allen JP, Schneider LW, Stavchansky SA. Rate of phenytoin accumulation in man: A simulation study. J Pharm Biopharm 1978;6:399-415.
4. Valodia P, Seymour MA, Miller R, McFadyen ML, Folb PI. Factors influencing the population pharmacokinetic parameters of phenytoin in adult epileptic patients in South Africa. Ther Drug Monit 1999;21:57-62.
5. Yuen GJ, Latimer PT, Littlefield LC, Mackay RW. Phenytoin dosage predictions in pediatric patients. Clin Pharmacokinet 1989; 16:254-60.
6. Vozeh S, Miur KT, Sheiner LB, Follath F. Predicting individual phenytoin dosage. J Pharmacokinet Biopharm 1981;9:131-46.
7. Grasela TH, Sheiner LB, Rambeck B, et al. Steady-state pharmacokinetics of phenytoin from routinely collected patient data. Clin Pharmacokinet 1983;8:355-64.
8. Sheiner LB, Beal SL, Evaluation of methods for estimating population pharmacokinetic parameters. I. Michaelis-Menten model: routine clinical pharmacokinetic data. J Pharmacokinet Biopharm 1980;8:553-71.
9. Yukawa E, Higuchi S, Aoyama T. Population pharmacokinetics of phenytoin from routine clinical data in Japan: An update. Chem Phann Bull 1990;38:1973-76.
10. Beal SL, Sheiner LB, Boeckmann AJ. NONMEM Users Guide 3. NONMEM Project Group, University of California, San Francisco. 1988-1992.
11. Sheiner LB, Rosenberg B, Marathe VV, Peck C. Differences in serum digoxin concentrations between outpatients and inpatients: An effect of compliance? Clin Pharmacol Ther 1973;15:239-46.
12. Davidian M, Giltinan DM. Nonlinear models for repeated measurement data. New York: Chapman and Hall; 1995:186-87.
13. Miller R, Reeders M. Effect of source of population data in phenytoin dosage predictions in black patients. Clin Pharm 1989;8: 56-9.
14. Miller R, Rheeders M, Klein C, Suchet I. Population pharmacokinetics of phenytoin in South African black patients. S Afr Med J 1987;72:188-90.
15. Sheiner LB, Beal SL. Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm 1981;9:503-12.
16. Flint N, Lopez LM, Robinson JD, Williams C, Salem RB. Comparison of eight phenytoin dosing methods in institutionalized patients. Ther Drug Monit 1985;7:74-80.
17. Toscano JP, Jameson JP. Comparison of four single-point phenytoin dosage prediction techniques using computer-simulated pharmacokinetic values. Clin Pharm 1986;5:396-402.
18. Mawer GE, Mullen PW, Rodgers M, Robins AJ, Lucas SB. Phenvtoin dose adjustment in epileptic patients. Br J Clin Pharmac 1974;1:163-68.
19. Vozeh S, Berger M, Wenk M, Ritz R, Follath F. Rapid prediction of individual dosage requirements for lignocaine. Clin Pharmacokinet 1984;9:354-63.